Compare Cassava Sciences Inc (FLNA) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs IQIYI Inc - ADR — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: IQIYI Inc - ADR is far larger — about 24.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 4,964,108). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and IQIYI Inc - ADR for 55 Days on average.
| FLNA | IQ | |
|---|---|---|
Market Cap | $39.40M | $974.67M |
Volume | 759,018 | 4,964,108 |
Sector | Health | Media |
52-Week High | $4.64 | $2.35 |
52-Week Low | $0.68 | $0.86 |
Typical Hold Time | 37 Days | 55 Days |
Enterprise Value | -$43.28M | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
iQIYI (IQ) trades at $1.015, up 0.5% with neutral technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million in 2025. Valuation metrics show mixed signals with low P/S (0.25) and P/B (0.52) ratios but elevated P/E (144.05) due to negative earnings. Recent news highlights AI-driven content expansion with over 350 new titles announced for 2026-2027.
Investment outlook remains cautious despite analyst consensus leaning bullish (50% buy ratings). The streaming business faces revenue pressure with 2026 projections showing -3.22% net margin, though AI content initiatives could improve cost structure. Key risks include Chinese regulatory environment and streaming competition. Institutional sentiment appears divided given mixed technical indicators and fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
